Efficacy and Safety of Selumetinib Compared with Current Therapies for Advanced Cancer: a Meta-analysis

  • Shen, Chen-Tian (Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital) ;
  • Qiu, Zhong-Ling (Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital) ;
  • Luo, Quan-Yong (Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital)
  • Published : 2014.03.01


Background and Aim: Selumetinib is a promising and interesting targeted therapy agent as it may reverse radioiodine uptake in patients with radioiodine-refractory differentiated thyroid cancer. We conduct this metaanalysis to compare the efficacy and safety of selumetinib with current therapies in patients with advanced cancer. Methods: An electronic search was conducted using PubMed/ Medicine, EMBASE and Cochrane library databases. Statistical analyses were carried out using either random-effects or fixed-effects models according to the heterogeneity of eligible studies. Results: Six eligible trials involved 601 patients were identified. Compared with current therapies, treatment schedules with selumetinib did not improve progression free survival (hazard ratio, 0.91; 95%CI 0.70-1.17, P= 0.448), but did identify better clinical benefits (odds ratio, 1.24; 95%CI 0.69-2.24, P = 0.472) and less disease progression (hazard ratio, 0.72; 95%CI 0.51-1.00, P = 0.052) though its impact was not statistically significant. Sub-group analysis resulted in significantly improved progression free survival (hazard ratio, 0.61; 95%CI 0.49-0.57, P = 0.00), clinical benefits (odds ratio, 3.04; 95%CI 1.60-5.77, P = 0.001) and reduced disease progression (hazard ratio, 0.35; 95%CI 0.18-0.67, P = 0.001) in patients administrated selumetinib. Dermatitis acneiform (risk ratio, 9.775; 95%CI 3.143-30.395, P = 0.00) and peripheral edema (risk ratio, 2.371; 95%CI 1.690-3.327, P = 0.00) are the most frequently observed adverse effects associated with selumetinib. Conclusions: Compared with current chemotherapy, selumetinib has modest clinical activity as monotherapy in patients with advanced cancer, but combinations of selumetinib with cytotoxic agents in patients with BRAF or KRAS mutations hold great promise for cancer treatment. Dermatitis acneiform and peripheral edema are the most frequently observed adverse effects in patients with selumetinib.


  1. Fremin C, Meloche S (2010). From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol, 3, 8.
  2. Farley J, Brady WE, Vathipadiekal V, et al (2013). Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol, 14, 134-40.
  3. Flaherty KT, Lee SJ, Zhao F, et al (2013). Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol, 31, 373-9.
  4. Flaherty KT, Schiller J, Schuchter LM, et al (2008). A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res, 14, 4836-42.
  5. Copas J, Shi JQ (2000). Meta-analysis, funnel plots and sensitivity analysis. Biostatistics, 1, 247-62.
  6. Berlin JA (1995). Invited commentary: benefits of heterogeneity in metaanalysis of data from epidemiologic studies. Am J Epidemiol, 142, 383-7.
  7. Bodoky G, Timcheva C, Spigel DR, et al (2012). A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs, 30, 1216-23.
  8. Chang L, Karin M (2001). Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
  9. Curtin JA, Fridlyand J, Kageshita T, et al (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med, 353, 2135-47.
  10. Davies H, Bignell GR, Cox C, et al (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949-54.
  11. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  12. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D (2013). MEK and the inhibitors: from bench to bedside. J Hematol Oncol, 6, 27.
  13. Almoguera C, Shibata D, Forrester K, et al (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53, 549-54.
  14. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA, 92, 7686-9.
  15. English J, Pearson G, Wilsbacher J, et al (1999). New insights into the control of MAP kinase pathways. Exp Cell Res, 253, 255-70.
  16. Peyssonnaux C, Eychene A (2001). The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell, 93, 53-62.
  17. Moher D, Pham B, Jones A, et al (1998). Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet, 352, 609-13.
  18. O'Neil BH, Goff LW, Kauh JS, et al (2011). Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 29, 2350-6.
  19. Pearson G, Robinson F, Beers Gibson T, et al (2001). Mitogenactivated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev, 22, 153-183.
  20. Pimienta G, Pascual J (2007). Canonical and alternative MAPK signaling. Cell Cycle, 6, 2628-32.
  21. Raman M, Chen W, Cobb MH (2007). Differential regulation and properties of MAPKs. Oncogene, 26, 3100-12.
  22. Robert C, Dummer R, Gutzmer R, et al (2013). Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol, 14, 733-40.
  23. Robins J, Greenland S, Breslow NE (1986). A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol, 124, 719-23.
  24. Bekaii-Saab T, Phelps MA, Li X, et al (2011). Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol, 29, 2357-63.
  25. Bennouna J, Lang I, Valladares-Ayerbes M, et al (2011). A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs, 29, 1021-8.
  26. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006). Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods, 11, 193-206.
  27. Hainsworth JD, Cebotaru CL, Kanarev V, et al (2010). A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol, 5, 1630-6.
  28. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  29. Ho AL, Grewal RK, Leboeuf R, et al (2013). Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med, 368, 623-32.
  30. Janne PA, Shaw AT, Pereira JR, et al (2013). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol, 14, 38-47.
  31. Kirkwood JM, Bastholt L, Robert C, et al (2012). Phase II, openlabel, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res, 18, 555-67.
  32. Krishna M, Narang H (2008). The complexity of mitogenactivated protein kinases (MAPKs) made simple. Cell Mol Life Sci, 65, 3525-44.
  33. Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG (2006). Novel targets in solid tumors: MEK inhibitors. Clin Adv Hematol Oncol, 4, 831-6.
  34. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol, 62, 1006-12.
  35. Wortzel I, Seger R (2011). The ERK cascade: distinct functions within various subcellular organelles. Genes Cancer, 2, 195-209.
  36. Shaul YD, Seger R (2007). The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta, 1773, 1213-26.
  37. Smit VT, Boot AJ, Smits AM, et al (1988). KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res, 16, 7773-82.
  38. Wang D, Boerner SA, Winkler JD, Lorusso PM (2007). Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta, 1773, 1248-55.
  39. Wright CJ, McCormack PL (2013). Trametinib: first global approval. Drugs, 73, 1245-54.
  40. Yeh TC, Marsh V, Bernat BA, et al (2007). Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogenactivated protein kinase kinase 1/2 inhibitor. Clin Cancer Res, 13, 1576-83.
  41. Robinson MJ, Cobb MH (1997). Mitogen-activated protein kinase pathways. Curr Opin Cell Biol, 9, 180-6.
  42. Schaeffer HJ, Weber MJ (1999). Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol, 19, 2435-44.

Cited by

  1. Advances in small molecule therapy for treating metastatic thyroid cancer vol.18, pp.11, 2017,